🏠 Home 📋 All Cases 🧠 Psychotropic & BP Module
Prescribing Decision — Hypertension
34

The 'Safer' Switch That Made It Worse

Why the non-stimulant label does not mean what it sounds like

Presentation

A 34-year-old woman with ADHD has taken lisdexamfetamine 50 mg daily for four years with good symptom control. At a routine visit her blood pressure is montage-confirmed 148/94 on repeat readings, and home monitoring confirms stage 1 hypertension. She has CKD stage 2 from reflux nephropathy.

Concerned about the stimulant, her psychiatrist switches her to atomoxetine 80 mg daily, explaining that a non-stimulant will be safer for her blood pressure.

Six weeks later

Home blood pressure is unchanged to slightly higher, resting heart rate has risen from 76 to 88, and her ADHD symptoms have worsened. She asks whether the switch was worth it.

Questions

1

Was the reasoning behind the switch pharmacologically sound?

A) Yes — non-stimulants reliably have less cardiovascular effect
B) No — atomoxetine is a pure norepinephrine transporter inhibitor
C) Yes, but the dose chosen was too high
D) No — atomoxetine should have been combined with the stimulant
Correct Answer: B
Learning Point: Atomoxetine is a selective NET inhibitor — blocking norepinephrine reuptake is precisely the mechanism that raises blood pressure and heart rate. In a network meta-analysis of 102 trials, amphetamines, lisdexamfetamine, and methylphenidate were not associated with larger haemodynamic increments than atomoxetine or viloxazine, and atomoxetine produced the largest pulse increase of any agent studied in children (+5.58 bpm). The category name describes the abuse-liability profile, not the haemodynamics.
📚 Reference: Lecture: Psychiatric & ADHD Medications and Blood Pressure
2

Which ADHD medication would be expected to LOWER her blood pressure?

A) Viloxazine
B) Methylphenidate
C) Guanfacine extended-release
D) Modafinil
Correct Answer: C
Learning Point: Guanfacine is an alpha-2 agonist — a licensed antihypertensive that also treats ADHD. In the same network meta-analysis it produced decrements in every haemodynamic parameter, with a mean adult systolic decrease of about 10 mmHg versus placebo. Viloxazine is another NET inhibitor and behaves like atomoxetine.
📚 Reference: Clinical Mastery: Psychotropic and ADHD Medications in Hypertension and CKD — Section 4.3
3

If guanfacine is started, what must be actively managed?

A) Her potassium, because alpha-2 agonists cause hyperkalemia
B) Her other antihypertensives may need to be reduced, and she should be watched for bradycardia and postural dizziness
C) Her lisdexamfetamine must be tapered over 6 months first
D) Nothing — guanfacine has no cardiovascular monitoring requirements
Correct Answer: B
Learning Point: The two-birds prescription has a trap. In long-term adult use, decreased blood pressure, postural dizziness, and bradycardia were among the commonly reported adverse events. If guanfacine is started in a patient already on antihypertensives, the regimen may need to come down, not up — and this requires coordination with psychiatry rather than parallel prescribing.
📚 Reference: Student Handout — Section 4
4

Her CKD is stage 2 now but may progress. Which statement about guanfacine in advanced kidney disease is correct?

A) It requires 50% dose reduction below eGFR 30
B) It is contraindicated in dialysis
C) No major dose adjustment is needed — non-renal elimination compensates
D) It must be dosed only after dialysis sessions
Correct Answer: C
Learning Point: Across the GFR spectrum, guanfacine's renal clearance collapses more than tenfold (233 → 34 → 18 mL/min) and urinary excretion falls from 57% to 7.5% — yet total body clearance is largely preserved and the elimination half-life stays at 14 hours independent of renal function, because non-renal elimination takes over. Note the wide variability in these small studies: 'no major adjustment' means start low and titrate, not that monitoring is unnecessary.
📚 Reference: Clinical Mastery: Psychotropic and ADHD Medications in Hypertension and CKD — Section 7.3
5

She asks whether staying on a stimulant long-term would have damaged her heart. What is the most accurate answer?

A) Yes — stimulants clearly increase heart attack and stroke risk
B) No hard-event excess has been shown, but long-term use is associated with developing hypertension
C) There is no evidence of any cardiovascular effect whatsoever
D) Risk applies only to patients over 65
Correct Answer: B
Learning Point: Two very large cohorts (1.2 million children and young adults; 150,000 adults) found no increase in myocardial infarction, stroke, or sudden death. But a case-control study of 278,027 people found the risk of incident hypertension rose with cumulative duration — about 1.8-fold beyond 5 years. These do not conflict: a drug adding roughly 2 mmHg and 4 bpm will not rupture a plaque this year, but it shifts the pressure distribution over a decade. For a patient with CKD, that slow shift is the outcome that matters most.
📚 Reference: Clinical Mastery: Psychotropic and ADHD Medications in Hypertension and CKD — Section 4.4

Take-Home

Choose by mechanism, not by category

“Stimulant” versus “non-stimulant” is a regulatory and abuse-liability distinction, not a haemodynamic one. The question that predicts blood pressure is always the same: does this drug block norepinephrine reuptake? Atomoxetine and viloxazine do. Guanfacine and clonidine do the opposite.

What the evidence cannot tell you: there are no studies of ADHD medications in CKD or dialysis populations. Every renal recommendation in this area is inferred from elimination pathways. Say so when you counsel the patient — an acknowledged gap is more useful than a confident number you cannot source.

Andrew Bland, MD, FACP, FAAP

Medical Associates Department of Nephrology · University of Illinois College of Medicine at Peoria · University of Dubuque PA & DPT Programs · Butler College of Osteopathic Medicine

Interactive teaching case · Psychotropic & ADHD Medications and Blood Pressure

© 2026 · urinenephrology.org